EXHIBIT A

		1
1	IN THE UNITED STATES DISTRICT COURT	
2	FOR THE DISTRICT OF MASSACHUSETTS	
3	ABBOTT GMBH & CO., KG,	
4	ABBOTT BIORESEARCH CENTER, INC. :	
5	AND ABBOTT BIOTECHNOLOGY LTD., :	
6	Plaintiffs :	
7	v. : Civil Action No.	
8	CENTOCOR ORTHO BIOTECH, INC. : 4:09-CV-11340-FDS	
9	AND CENTOCOR BIOLOGICS, LLC :	
10	Defendants :	
11		
12	Videotaped Deposition of THOMAS CLINTON NESSPOR, Ph.D.	
13	Philadelphia, Pennsylvania	
14	Friday, February 11, 2011	
15	9:43 a.m.	
16	Job No.: 1-193913	
17	Pages: 1 - 142	
18	Reported By: Dawn M. Hart, Notary Public, RPR/RMR	
19	Videographer: David Lane	
20		
21		
22		

	106
1	A I'm sorry, it must be the time of day. I'm
2	going to have to ask you to repeat the question.
3	Q Sure. So just reading the figure legend for
4	Figure 2, the first sentence, does it state, the top
5	portion shows a comparison of the 12B75 heavy chain
6	variable region sequence to the DP-73 germline
7	variable region sequence?
8	A Yes, that's what's stated.
9	Q And this comparison of the 12B75 sequence to
10	the DP-73 sequence, how was that comparison performed?
11	MS. JOHNSON: Objection, vague.
12	A I believe it was performed using a computer
13	program which aligns amino acid sequences based on
14	their similarity.
15	Q Okay. And someone would have input the
16	12B75 sequence into this computer program; is that
17	correct?
18	A I'd like to ask you to be more precise about
19	what you mean by input.
20	Q Sure. Actually, strike that question.
21	This computer program so is it correct
22	that a computer program was used to compare the 12B75

107 1 amino acid sequence to this DP-73 germline sequence? MS. JOHNSON: Objection, vague. 2 3 I do believe that to be the case. Α 4 Did you perform that comparison using the Q 5 computer program? 6 Α I can't recall. 7 Do you recall if Bernard Scallon performed 0 8 that comparison of the 12B75 germline sequence to the 9 DP-73 sequence? 10 Α No, it was definitely one of the two of us. 11 One of the two, either you or Bernard Q 12 Scallon? 13 Α That's correct. 14 So if we look at the 12B75 amino acid 15 sequence shown here, can you explain to me what is 16 represented by these various dots and letters? 17 Yes, I can. The germline sequence is given 18 on the top next to where it says 12B75. Anywhere that 19 the 12B75 amino acid matched the germline sequence in 20 that position, a dot was shown signifying that it was 21 the same amino acid. Anywhere that there was a 22 difference between the germline sequence and the

		108
1	sequence of 12B75, the difference that the amino	
2	acid that differed was shown.	
3	Q Okay. So the letters shown in bold for	
4	12B75 represent amino acids that are different from	
5	the DP-73 germline sequence; is that right?	
6	A Yes, that's correct.	
7	Q And what do these how did these	
8	differences strike that.	
9	What was the significance of these	
10	differences to you between the sequence of 12B75 and	
11	the germline DP-73 sequence?	
12	MS. JOHNSON: Objection, form.	
13	A I am going to have to ask you to be a little	
14	more specific	
15	Q Sure.	
16	A when you refer to significance.	
17	Q Let me strike that previous question.	
18	Did you expect to see differences between	
19	the 12B75 sequence and the DP-73 germline sequence?	
20	MS. JOHNSON: Objection, form.	
21	A Yes, we expected to see differences.	
22	Q Why did you expect to see differences?	

MS. JOHNSON: Same objection.

- A Antibodies which have gone through the process of affinity maturation to bind to a specific antigen, part of that affinity maturation involves the mutation of amino acids to be different than the germline sequence.
- Q Okay. And this affinity maturation process that you mentioned, that's something that happens inside, inside the mice?
- A Yes, that is a process that happens inside the mice.
 - Q And what do you mean by affinity maturation?
- A It's been a long time since Biology 101 but the, in the process of -- in the process of an antibody gaining its specificity to an antigen, it goes through a specific process called affinity maturation to allow it to bind strongly to the antigen inside -- in vivo in this animal.
- Q And this affinity maturation, does this involve mutations in the antibody sequence?
- A I don't feel I can answer specific questions about affinity maturation. I'm just not familiar

		110
1	enough with the concept.	
2	Q Are you familiar with the concept of somatic	
3	mutation?	
4	A I wish I could say yes but I'm going to say	
5	that I couldn't tell you exactly what's meant by	
6	somatic mutation at this time.	
7	Q Okay. So you mentioned that these	
8	differences between the 12B75 amino acid sequence and	
9	the DP-73 germline sequence were expected; is that	
10	correct? Not let me rephrase that.	
11	That you expected to see some differences	
12	between the 12B75 amino acid sequence and the DP-73	
13	germline sequence?	
14	MS. JOHNSON: Objection, vague.	
15	A Yes.	
16	Q And you mentioned that this, the, these	
17	differences in the amino acid sequence of 12B75	
18	compared to the DP-73 germline sequence were	
19	associated with affinity maturation; is that correct?	
20	MS. JOHNSON: Objection, form.	
21	A That's my understanding.	
22	Q And does the affinity maturation result in	

		111
1	generation of antibodies with higher affinity than the	
2	starting antibody?	
3	MS. JOHNSON: Objection, calls for expert	
4	testimony.	
5	A I'm going to say that I don't have the	
6	knowledge to, to accurately answer that question.	
7	Q Okay. So this figure illustrates, as we've	
8	discussed already, the sequence, a sequence comparison	
9	of the 12B75 heavy chain sequence to the DP-73	
10	germline sequence. Do you know why you compared this	
11	12B75 sequence to DP-73 in particular as opposed to	
12	any of the other germline variable sequences?	
13	A My recollection is that we compared the	
14	12B75 heavy chain variable region sequence to all of	
15	the germline sequences that we were aware of in the	
16	GenPharm mice, and that the DP-73 germline sequence	
17	was, had the greatest homology to the 12B75 sequence.	
18	Q And what did that indicate to you?	
19	MS. JOHNSON: Objection, form.	
20	A I guess I don't understand the question.	
21	Q Did that indicate to you that the 12B75	
22	antibody was likely derived from the DP-73 germline	

		112
1	sequence?	
2	MS. JOHNSON: Objection, form.	
3	A Yes.	
4	Q Okay. Did you consider comparing the 12B75	
5	sequence to any other germline sequences other than	
6	the germline sequences of the GenPharm mice?	
7	A No.	
8	Q If you could turn to Figure 3 on the next	
9	page which is Page 14 of the Technical Report and this	
10	is ending in Bates No. 14913.	
11	A (Complying.)	
12	Q If you could just take a look at Figure 3	
13	and the legend for that and let me know when you've	
14	reviewed that.	
15	A (Reviewing.)	
16	I'm sorry, did you ask me to read that?	
17	Q If you could just take a look at the legend	
18	for Figure 3 and Figure 3, and let me know when you're	
19	done.	
20	A (Reviewing.)	
21	I'm done.	
22	Q So this figure also demonstrates a	

		113
1	comparison of the 12B75 sequence to a germline	
2	sequence; is that correct?	
3	MS. JOHNSON: Objection, form.	
4	A Yes.	
5	Q And how does this differ from what's shown	
6	in Figure 2?	
7	A This is the light chain amino acid sequence	
8	compared to a light chain germline sequence, and	
9	Figure 2 was a heavy chain amino acid sequence	
10	compared to a heavy chain germline sequence.	
11	Q Okay. And what was the germline sequence	
12	that was used for comparison in this figure, Figure 3?	
13	A According to the legend this sequence was	
14	designated DPK7/HK134/HK166.	
15	Q And what is that sequence? What is	
16	DPK7/HK134/HK166?	
17	A I don't recall what that long designation	
18	specifically refers to.	
19	Q Okay. Is it a germline sequence of a light	
20	chain from the GenPharm mice?	
21	A Yes, I believe that to be the case.	
22	Q And the figure, if you could look again at	